Tisagenlecleucel – VJRegenMed

Outcomes of children and young adults with B-ALL following tisa-cel reinfusion

Anya Kerkache — Thu, 09 Mar 2023 11:31:48 +0000

Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, shares the results of a retrospective study evaluating the safety and efficacy of tisagenlecleucel (tisa-cel) reinfusion in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL). Overall, the study showed that second CAR-T infusions were well tolerated, allowed patients to achieve a complete remission (CR) or re-establish B-cell aplasia (BCA), and could be used as a bridge to transplant. However, most remissions were brief and BCA was limited. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

Anya Kerkache — Thu, 26 Jan 2023 12:12:01 +0000

Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Engineering NK cell-based cancer treatments

Simon Ng — Tue, 12 Apr 2022 11:18:06 +0000

Juliane Mietz, University Of Zurich, Zurich, Switzerland, comments on ongoing research to develop anti-cancer natural killer (NK) cell therapies. Chimeric antigen receptor (CAR)-NK cells were initially studied alongside CAR T-cell, where both were engineered with CD28 or a 4-1BB costimulatory domains, domains found in axicabtagene ciloleucel and tisagenlecleucel, to assess the clinical efficacy of CAR-NK cells. Further pre-clinical studies involving CAR-NK cells are additionally underway to enhance their cytotoxicity in patients. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Accelerating commercialization in advanced therapies

admin_vjr_user — Sat, 10 Apr 2021 10:57:58 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes a panel discussion that took place at the Cell & Gene Meeting on the Mediterranean 2021 virtual conference, in which leading experts discussed how the field can accelerate the commercialisation of cell and gene therapies. He highlights challenges associated with the regulation of these innovative therapies and proposes that regulatory agencies need to work closely with the industry in order to establish the critical criteria required to demonstrate the efficacy and safety of cell and gene therapies. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

An overview of the CAR T-cell therapy story

Marta Palhas — Fri, 26 Feb 2021 14:08:22 +0000

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an overview of the CAR T-cell therapy story so far. The introduction of CAR T-cell therapy was a real revolution in the field of hematology. Following the breakthrough clinical results in the pivotal trials, the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have approved two anti-CD19 CAR T-cell products: tisagenlecleucel for the use in children and young adults up to 25 years of age with relapsed/refractory (R/R) acute lymphoblastic leukemia, and tisagenlecleucel and axicabtagene ciloleucel for the use in adult patients with R/R diffuse large B-cell lymphoma. In addition, several clinical trials are currently investigating the use of CAR T-cells in other hematological malignancies. It is anticipated that other CAR T-cell products will soon be approved. This interview took place during the 3rd European CAR T-cell Meeting.

Practical aspects of CAR T-cell therapy

Marta Palhas — Fri, 26 Feb 2021 14:08:21 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, gives an overview of the topics discussed in the session he chaired on practical aspects of CAR T-cell therapy. CAR T-cell immunotherapy has radically altered the treatment of B-cell malignancies. Prof. Jäger outlines that in the setting of diffuse large B-cell lymphoma, the approved CAR-T products are being integrated into daily clinical practice. However, patient selection remains a challenge in the field. The new and exciting field of BCMA CAR T-cells in multiple myeloma was also addressed during the session. This interview took place during the 3rd European CAR T-cell Meeting.

The challenges of CAR T-cell therapy for pediatric B-ALL

Marta Palhas — Fri, 26 Feb 2021 14:08:21 +0000

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining challenges. In addition, CD19 negative relapses are another challenge that needs to be tackled. Dr Ghorashian goes on to discuss strategies for dual CAR targeting, in particular CD19CAT and CD22 CAR T-cells. This interview took place during the 3rd European CAR T-cell Meeting.

Updates on CAR T-cell therapy in B-cell malignancies

Marta Palhas — Fri, 26 Feb 2021 14:08:20 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the progress and future directions in CAR T-cell therapy for the treatment of B-cell malignancies. The availability of CAR-T has altered the current treatment algorithm for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Indications will likely expand to other disease entities and earlier lines of therapy. Future directions include products targeting multiple tumor antigens to overcome resistance. This interview took place during the 3rd European CAR T-cell Meeting.

CAR-T therapy for aggressive B-cell lymphomas

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third-line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Anti-CD19 CAR T-cells for adults

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults with lymphoma and leukemia, specifically discussing the sustained remissions seen in patients treated with tisagenlecleucel and axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).